⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 20, 2024Deleted JournalOpen Access

Comparing efficacy and safety of in-house gemcitabine to mitomycin for bladder instillation in intermediate-risk NMIBC

Carla Abou Chaaya Saïd Ourfali Chloé Marchand Camille Merienne A. Ruffion Hugo Brouzes N. Abid Fabrice Pirot Marc Colombel

View Full Paper

Ask AI

Bookmark

Share

Abstract

Intermediate-risk (IR) Non-Muscle Invasive Bladder Cancer (NMIBC) is associated with a high rate of tumor recurrence. To improve patient outcomes, it is recommended to use adjuvant intravesical therapy, by mitomycin C (MMC) or Bacillus Calmette Guerin (BCG). Gemcitabine (GMC) is a known molecule used in urothelial cancer. We aimed to study the efficacy and safety profile of a gemcitabine solution, compared to mitomycin C, in the treatment of IR NMIBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chaaya et al. (2024) studied this question.

synapsesocial.com/papers/68e5fa66b6db64358758e8b9 https://doi.org/10.1016/j.fjurol.2024.102699

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancerOriginal Research · 2026
2Comparison of Long-Term Oncological Outcomes of Intravesical Bacillus Calmette–Guérin Versus Gemcitabine in Treatment-Naïve Non-Muscle-Invasive Bladder Cancer with Intermediate and High Risk: A Multicenter Retrospective AnalysisCohort Study · 2026
3Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study2024 · 4 citations
4IMGeS study: A prospective, multicentre, phase II trial of sequential intravesical mitomycin-C and gemcitabine therapy in BCG-unresponsive high-risk NMIBC ineligible for or declining radical cystectomy.Human Clinical Trial · 2026
5Sequential intravesical Bacillus Calmette-Güerin and mitomycin C applied with electromotive drug administration therapy for non-muscle invasive bladder cancer2025 · 1 citations

More related papers

Gemcitabine versus Bacillus Calmette-Guérin (BCG) in Non Muscle Invasive Transitional Cell Carcinoma of the Bladder after Trans-Urethral Resection2024
Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning2026
A prospective comparative study of intravesical chemotherapy versus immunotherapy in non-muscle invasive bladder cancer2025